Clinical Edge Journal Scan

Site of infection linked to PsA onset regardless of pathogen


 

Key clinical point: Having sent a pharyngeal sample for culture was associated with an increased risk for psoriatic arthritis (PsA) onset, indicating site of infection being associated with the increased PsA risk rather than the pathogen.

Major finding: Among all samples sent for culture, a pharyngeal sample was associated with a higher risk for PsA onset within first 50 days compared with a urine (hazard ratio [HR] 8.78; 95% CI 3.23-23.91), nasopharyngeal (HR 8.26; 95% CI 2.23-30.63), or blood (HR 25.22; 95% CI 3.12-204.13) sample; however, streptococcal infections in the pharynx or at any other site were not associated with an increased risk for PsA.

Study details: Findings are from a population-based cohort study including 313,235 bacterial cultures from 128,982 individuals.

Disclosures: The study was supported by the Landspitali University Hospital, Iceland. A Ogdie and T Love declared serving as consultants and receiving grants and reimbursement from several sources.

Source: Thrastardottir T et al. Strong site-specific association of pharyngeal cultures with the onset of psoriatic arthritis and psoriasis, regardless of pathogen. Rheumatology (Oxford). 2022 (Apr 23). Doi: 10.1093/rheumatology/keac253

Recommended Reading

Clinical Edge Journal Scan Commentary: PsA May 2022
MDedge Rheumatology
Parents’ autoimmune diseases may affect children’s development
MDedge Rheumatology
Upadacitinib earns FDA approval for ankylosing spondylitis 
MDedge Rheumatology
Reduced-frequency methotrexate monitoring causes no harm
MDedge Rheumatology
‘Shielding’ status provides best indicator of COVID-19 mortality in U.K. arthritis population
MDedge Rheumatology
Severe infections often accompany severe psoriasis
MDedge Rheumatology
FDA approves topical tapinarof for plaque psoriasis
MDedge Rheumatology
Improved outcomes with 6-month secukinumab use in PsA
MDedge Rheumatology
Sex and BMI affect response to systemic PsA therapy
MDedge Rheumatology
PsA: Real-world efficacy, safety, and retention rate of secukinumab
MDedge Rheumatology